Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2015 02:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance

Solid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing operations[2] Net sales were USD 12.3 billion (-6%, +6% cc) Operating income was USD 2.2 billion (-18%, +2% cc)...
October 23, 2015 07:25 ET | Source: NOVARTIS FINANCE S.A.

Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis

Cosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients Cosentyx demonstrated rapid onset of action...
September 25, 2015 01:15 ET | Source: NOVARTIS FINANCE S.A.

Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval

Positive opinion from EU review body puts Entresto on track to be approved for HFrEF patients across Europe likely by year end Entresto was studied in world's largest heart ...
September 24, 2015 12:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires

New leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E....
July 21, 2015 01:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches

Sales, core[1] operating income and core EPS grew (cc[1]) for continuing operations[2] in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD...
July 07, 2015 16:33 ET | Source: NOVARTIS FINANCE S.A.

Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization

First in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only...
April 23, 2015 01:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio

Continuing operations[1] saw sales, core[2] operating income and core EPS grow (cc[2]) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc)[2] Operating income was USD 2.8 billion (-1%, +15% cc)...
April 16, 2015 12:26 ET | Source: NOVARTIS FINANCE S.A.

Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg

Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full range of...
March 06, 2015 09:10 ET | Source: NOVARTIS FINANCE S.A.

FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz

Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the...
February 13, 2015 11:30 ET | Source: NOVARTIS FINANCE S.A.

Novartis' heart failure medicine LCZ696 granted FDA priority review

Decision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Filing is based on results from the landmark PARADIGM-HF study[1] Nearly...